SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 657.80+1.7%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (3189)12/21/2020 3:28:07 PM
From: CuttingEdge Bio  Read Replies (1) of 3557
 
That's not really true. They tried and failed to show superiority in BCVA. They did not attempt a "personal dosing" combo vs. standard dosing eylea and generate percentages of duration, as Roche did here (personal dosing bispec vs. SOC standard dosing). Presumably REGN could achieve this same result with the same trial design.
But the failure of phase 2 to show advantage in terms of BCVA of combo over mono, puts restrictions on what you can do with a combo for further development.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News